TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06596473: A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients With Selected Advanced Sol

Sponsor: BeOne Medicines · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 310 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$7,194,264

Rescue Site Savings

+$4,743,816

Unlock Full NCT06596473 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06596473 Rescue Dossier →